Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca

Veterinary Ophthalmology

Volumn 8, Issue 4, 2005, Pages 225-232

  Berdoulay, Andrew ^a   English, Robert V ^b   Nadelstein, Brad ^a  

^a Animal Eye Care Associates   (United States)

^b Animal Eye Care Associates   (United States)

Author keywords

Canine; Cyclosporine; FK506; Keratoconjunctivitis sicca; Tacrolimus; Tear production

Indexed keywords

EYE DROPS; TACROLIMUS;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; KERATOCONJUNCTIVITIS SICCA; LACRIMAL FLUID; MALE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SECRETION; TREATMENT OUTCOME;

ANIMALS; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; KERATOCONJUNCTIVITIS SICCA; MALE; OPHTHALMIC SOLUTIONS; TACROLIMUS; TEARS; TREATMENT OUTCOME;

ANIMALIA; CANIS FAMILIARIS;

EID: 22244451981     PISSN: 14635216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2005.00390.x     Document Type: Article

References (53)

1. Ludders JW, Heavner JE. Effect of atropine on tear formation in anesthetized dogs. Journal of the American Veterinary Medical Association 1979; 175: 585-586.
2. Vetsre WA, Brightman AH, Helper LC. Decreased tear production associated with general anesthesia in the dog. Journal of the American Veterinary Medical Association 1979; 174: 1006-1007.
3. Kern TJ, Erb HN. Facial neuropathy in dogs and cats: 95 cases (1975-85). Journal of the American Veterinary Medical Association 1987; 191: 1604-1609.
4. Morgan RV, Duddy JM, McClug K. Prolapse of the gland of the third eyelid in dogs. A retrospective study of 89 cases (1980-90). Journal of the American Animal Hospital Association 1993; 29: 56-60.
5. Peruccio C. Incidence of hypothyroidism in dogs affected by keratoconjunctivitis sicca (Abstract). Annual Meeting of the American College of Veterinary Ophthalmologists 1982; 13: 47-48.
6. Barrera R, Mane M, Rodriguez JF et al. Keratoconjunctivitis sicca and diabetes mellitus in a dog. Journal of the American Veterinary Medical Association 1992; 200: 1967-1968.
7. Roberts SM, Lavach JD, Severin GA et al. Ophthalmic complications following megavoltage irradiation of the nasal and paranasal cavities in dogs. Journal of the American Veterinary Medical Association 1987; 190: 43-47.
8. Martin CL, Kaswan RL. Distemper-associated keratoconjunctivitis sicca. Journal of the American Animal Hospital Association 1985; 21: 355-359.
9. Gelatt KN, Gwin RM. Canine lacrimal and nasolacrimal systems. In: Veterinary Ophthalmology, 2nd edn. (ed. Gelatt KN) Lea & Febiger, Philadelphia, 1991; 309-329.
10. Aquirre GD, Rubin LF, Harvey CE. Keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1971; 158: 1566-1569.
11. Kaswan RL, Martin CL, Chapman WL. Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs. American Journal of Veterinary Research 1984; 45: 112-118.
12. Kaswan RL, Martin CL, Dawe DL. Keratoconjunctivitis sicca: immunologic evaluation of 62 cases. American Journal of Veterinary Research 1985; 46: 376-383.
13. Izci C, Celik I, Alkan F et al. Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca. American Journal of Veterinary Research 2002; 63: 688-693.
14. Bounous DI, Carmichael KP, Kaswan RL et al. Effects of ophthalmic cyclosporine on lacrimal gland pathology and function in dogs with keratoconjunctivitis sicca. Veterinary and Comparative Ophthalmology 1996; 5: 5-12.
15. Moore CP. Disease and surgery of the lacrimal secretory system. In: Veterinary Ophthalmology, 3rd edn. (ed. Gelatt KN) Lippincott Williams & Wilkins, Baltimore, 1999; 583-607.
16. Severin GA. Keratoconjunctivitis sicca. In: Severin's: Veterinary Ophthalmology Notes, 3rd edn. (ed. Mawhiney H) DesignPointe™ Communications, Fort Collins, 1996; 230-233.
17. Salisbury MA, Kaswan RL, Ward DA et al. Topical application of cyclosporine in the management of keratoconjunctivitis sicca in dogs. Journal of the American Animal Hospital Association 1990; 26: 269-274.
18. Morgan RV, Abrams KL. Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1991; 199: 1043-1046.
19. Olivero DK, Davidson MG, English RV et al. Clinical evaluation of 1% cyclosporine for topical treatment of keratoconjunctivitis sicca in dogs. Journal of the American Veterinary Medical Association 1991; 199: 1039-1092.
20. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cysclosporine eye drops. Archives of Ophthalmology 1989; 107: 1210-1216.
21. Rubin LF, Aguirre G. Clinical use of pilocarpine for keratoconjunctivitis sicca in dogs and cats. Journal of the American Veterinary Medical Association 1967; 151: 313-320.
22. Gelatt KN. Treatment of canine keratoconjunctivitis sicca by parotid duct transposition. Journal of the American Animal Hospital Association 1970; 6: 1-12.
23. Sansom J, Barnett KC, Neumann W et al. Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial. Veterinary Record 1995; 137: 504-507.
24. Kaswan RL, Salisbury MA. A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine. Veterinary Clinics of North America 1990; 20: 583-613.
25. Moore CP, McHugh JB, Thorne JG et al. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model. Investigative Ophthalmology and Visual Science 2001; 42: 653-659.
26. Gao J, Schwalb TA, Addeo JV et al. The role of apoptosis in the pathogenesis of canine keratoconjnctivitis sicca: the effect of topical cyclosporin A therapy. Cornea 1998; 17: 654-663.
27. Kino T, Hatanaka H, Miyata S et al. FK506, a novel immunosuppressant isolated from Streptomyces. I. Fermentation, isolation, and physio-chemical and biological characteristics. Journal of Antibiotics 1987; 60: 1249.
28. Tocci MJ, Matkovich DA, Collier KA et al. The immunosuppressant FK506 selectively inhibits expression of early T-cell activation genes. Journal of Immunology 1989; 143: 718-726.
29. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunology Today 1992; 13: 146-141.
30. Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Investigative Ophthalmology and Visual Science 1988; 29: 1265-1271.
31. Hikita N, Lopez JS, Chan CC et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Investigative Ophthalmology and Visual Science 1997; 38: 901-908.
32. Hikita N, Chan CC, Whitcup SM et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. Current Eye Research 1995; 14: 209-214.
33. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocular Immunology and Inflammation 1998; 6: 101-109.
34. Reinhard T, Reis A, Mayweg S et al. Topical FK506 in inflammatory corneal and conjunctival diseases. A pilot study. Klinische Monatsblatter fur Augenheilkunde 2003; 219: 125-131.
35. Ogawa Y, Okamoto S, Kuwana M et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 2001; 20: 430-434.
36. Yang J, Shikata N, Yasuda T et al. Sjögren's syndrome in mice carrying the Iprcg gene and the therapeutic efficacy of an immunosuppressive agent, FK506. Pathology International 1999; 49: 133-149.
37. Hawkins EC, Murphy CJ. Inconsistencies in the absorptive capacities of Schirmer tear test strips. Journal of the American Veterinary Medical Association 1986; 188: 511-513.
38. Hakanson NW, Arnesson K. Temporal variation in tear production in normal beagle dogs as determined by Schirmer tear test. Veterinary and Comparative Ophthalmology 1997; 7: 196-203.
39. Chambers L, Fischer C, McCalla T et al. Topical tacrolimus in treatment of keratoconjunctivitis sicca: a multicenter preliminary clinical trial (poster). 33rd Annual Meeting of the American College of Veterinary Ophthalmologists 2002.
40. Sawada S, Suzuki G, Kawase Y et al. Novel immunosuppressive agent, FK506. Journal of Immunology 1987; 139: 1797-1803.
41. Kino T, Inamura N, Sakai F et al. Effect of FK506 on human mixed lymphocyte reaction in vitro. Transplantation Proceedings 1987; 19: 36-39.
42. Lauema AI, Surber C, Maibach HI. Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacology 1997; 10: 230-240.
43. Benitez del Castillo JM, del Aquila C, Duran S et al. Influence of topically applied cyclosporine A in olive oil on corneal epithelium permeability. Cornea 1994; 13: 136-140.
44. Vaden SL. Cyclosporine and tacrolimus. Seminars in Veterinary Medicine and Surgery 1997; 12: 161-166.
45. Fujisawa T, Saitoh Y, Urabe N et al. Dose study of the immunosuppression of FK506 in canine lung allotransplantation. Surgery Today 1993; 23: 338-343.
46. Morimoto T, Yamada F, Koboyashi T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. Transplantation Proceedings 1989; 21: 1059-1063.
47. Fukuse T, Hasegawa S, Hirai T et al. Optimal dose of FK506 in canine lung allotransplantation. Transplantation Proceedings 1992; 24: 1399-1400.
48. Thiru S, Collier DS, Calne R. Pathological studies in canine and baboon allograft recipients immunosuppressed with FK506. Transplantation Proceedings 1987; 19: 98-99.
49. Todo S, Murase N, Ueda Y. Effect of FK506 in experimental transplantation. Transplantation Proceedings 1988; 20: 215-219.
50. Misseghers BS, Binnington AG, Mathews KA. Clinical observations of the treatment of canine perianal fistulas with topical tacrolimus in 10 dogs. Canadian Veterinary Journal 2000; 41: 623-627.
51. Marsella R, Nicklin CF. Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. Veterinary Dermatology 2002; 13: 203-210.
52. Griffies JD, Mendelsohn CL, Rosenkrantz WS et al. Topical 0.1% tacrolimus for the treatment of discoid lupus erythematosus and pemphigus erythematosus in dogs. Journal of the American Animal Hospital Association 2004; 40: 29-41.
53. Adkins EA, Hendrix DVH, Stuffle L et al. An investigation of the safety and efficacy of topical ophthalmic application of tacrolimus in dogs (Abstract). Annual Meeting of the American College of Veterinary Ophthalmologists 2003; 34: 39.